EP3840793A1 - Magnesium alloy based implant and method of preparing an implant - Google Patents
Magnesium alloy based implant and method of preparing an implantInfo
- Publication number
- EP3840793A1 EP3840793A1 EP19758677.9A EP19758677A EP3840793A1 EP 3840793 A1 EP3840793 A1 EP 3840793A1 EP 19758677 A EP19758677 A EP 19758677A EP 3840793 A1 EP3840793 A1 EP 3840793A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- implant
- implant according
- magnesium
- magnesium alloy
- forming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007943 implant Substances 0.000 title claims abstract description 92
- 229910000861 Mg alloy Inorganic materials 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 22
- 239000007787 solid Substances 0.000 claims abstract description 14
- 239000011777 magnesium Substances 0.000 claims description 23
- 210000000845 cartilage Anatomy 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 15
- 229910052749 magnesium Inorganic materials 0.000 claims description 15
- 238000000231 atomic layer deposition Methods 0.000 claims description 10
- 210000000130 stem cell Anatomy 0.000 claims description 10
- 239000012535 impurity Substances 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 210000003321 cartilage cell Anatomy 0.000 claims description 7
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 7
- 239000011701 zinc Substances 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 239000008177 pharmaceutical agent Substances 0.000 claims description 5
- 230000001172 regenerating effect Effects 0.000 claims description 5
- 238000010146 3D printing Methods 0.000 claims description 4
- 238000002513 implantation Methods 0.000 claims description 4
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 229910000392 octacalcium phosphate Inorganic materials 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- YIGWVOWKHUSYER-UHFFFAOYSA-F tetracalcium;hydrogen phosphate;diphosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].OP([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O YIGWVOWKHUSYER-UHFFFAOYSA-F 0.000 claims description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 239000010408 film Substances 0.000 description 22
- 201000008482 osteoarthritis Diseases 0.000 description 15
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 230000007797 corrosion Effects 0.000 description 9
- 238000005260 corrosion Methods 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 229910001425 magnesium ion Inorganic materials 0.000 description 9
- 239000000956 alloy Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 208000012659 Joint disease Diseases 0.000 description 5
- 239000010409 thin film Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 210000003722 extracellular fluid Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241001286462 Caio Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000003848 cartilage regeneration Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005229 chemical vapour deposition Methods 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical group O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 1
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 description 1
- 101000844518 Homo sapiens Transient receptor potential cation channel subfamily M member 7 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 102100021760 Magnesium transporter protein 1 Human genes 0.000 description 1
- 101150017238 Magt1 gene Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 102000003611 TRPM7 Human genes 0.000 description 1
- -1 TRPM7 or MAGT1 Chemical class 0.000 description 1
- 102100034204 Transcription factor SOX-9 Human genes 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000009816 chondrogenic differentiation Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002674 endoscopic surgery Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 1
- 229950004847 navitoclax Drugs 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000010915 one-step procedure Methods 0.000 description 1
- 238000010883 osseointegration Methods 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000007750 plasma spraying Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 238000004549 pulsed laser deposition Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/047—Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/68—Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
- A61B17/80—Cortical plates, i.e. bone plates; Instruments for holding or positioning cortical plates, or for compressing bones attached to cortical plates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/082—Inorganic materials
- A61L31/086—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/146—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/68—Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
- A61B17/72—Intramedullary pins, nails or other devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/68—Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
- A61B17/84—Fasteners therefor or fasteners being internal fixation devices
- A61B17/846—Nails or pins, i.e. anchors without movable parts, holding by friction only, with or without structured surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/68—Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
- A61B17/84—Fasteners therefor or fasteners being internal fixation devices
- A61B17/86—Pins or screws or threaded wires; nuts therefor
- A61B17/866—Material or manufacture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/30004—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
- A61F2002/30011—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis differing in porosity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
- A61F2002/30766—Scaffolds for cartilage ingrowth and regeneration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00011—Metals or alloys
- A61F2310/00035—Other metals or alloys
- A61F2310/00041—Magnesium or Mg-based alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00389—The prosthesis being coated or covered with a particular material
- A61F2310/00592—Coating or prosthesis-covering structure made of ceramics or of ceramic-like compounds
- A61F2310/00796—Coating or prosthesis-covering structure made of a phosphorus-containing compound, e.g. hydroxy(l)apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00389—The prosthesis being coated or covered with a particular material
- A61F2310/00964—Coating or prosthesis-covering structure made of cartilage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- the present invention relates to an implant based on a magnesium alloy and a method of preparing an implant, in particular an implant that may be used in the treatment, amelioration or prevention of osteoarthrosis or related joint diseases.
- OA joint disease osteoarthrosis
- OA vascular endothelial growth factor-1
- TNFa inflammatory cytokines
- cartilage degradation and mineralization of the extracellular matrix Li, Y. et al. The Role of miRNAs in Cartilage Homeostasis. Curr Genomics. 2015 Dec; 16(6) : 393-404.
- Conventional treatments for OA rely on invasive surgical methods, including joint replacement by prosthesis, joint resurfacing or transferring articular cartilage from non-weight bearing regions of the body. Pharmaceutical treatment focuses on relieving pain, e.g. via non-steroidal anti-inflammatory drugs or cortisone injections, although this approach fails to address the underlying cause of the disease.
- Novel therapies to replace or restore the damaged tissue are attracting interest, such as tissue engineering, which involves the combination of cells, biomaterials and bioactive factors to aid cartilage replacement.
- tissue engineering involves the combination of cells, biomaterials and bioactive factors to aid cartilage replacement.
- a different approach would be to repair existing cartilage tissue by a regenerative therapy, rather than replace it.
- Magnesium (Mg) is a promising material for use in regenerative therapy (Zhao, D. et al. Current status on clinical applications of magnesium-based orthopaedic implants: A review from clinical translational perspective.
- Mg influences cell homeostasis and functionality. Mg deficiency is also implicated as a major risk factor for OA, involved in pathways such as inflammation and cartilage damage. Supplementation or localized infiltration of Mg appears to be effective for treating OA in animal models (Li, Y. et al.
- a medical device such as an implant, capable of providing a controlled release of magnesium in joints, which may be suitable for the treatment, amelioration or prevention of osteoarthrosis or related joint diseases.
- an object of the present invention is to provide an implant based on a magnesium alloy which may be able to provide a controlled release of magnesium (in particular magnesium ions) in joints, which may improve cartilage regeneration and/or which may be suitable for the treatment, amelioration or prevention of osteoarthrosis or related joint diseases.
- magnesium in particular magnesium ions
- the present inventors have made diligent studies for solving these objects and have found that a controlled release of magnesium ions (in particular an optimized degradation or corrosion rate (gradual dissolution) of the implant, such as exhibiting a slow initial corrosion after implantation and gradually increasing the corrosion), while at the same time providing a secure
- anchorage or attachment of the implant at the location of intended use can be achieved by configuring the implant with two distinct portions, one (first) portion being substantially solid which may be configured for fixing (attaching, adhering, anchoring) the implant in a body material, in particular a bone, and another (second) portion being substantially porous which may be configured for releasing magnesium ions, in particular in a controlled manner.
- the present invention relates to an implant based on a
- the present invention further relates to a method of preparing an implant based on a magnesium alloy comprising the steps of forming a first portion such that the first portion is substantially solid and forming a second portion such that the second portion is substantially porous.
- the expression “comprising”, as used herein, includes not only the meaning of “comprising”, “including” or “containing”, but also encompasses “consisting essentially of” and “consisting of”. Unless specifically stated otherwise, the expressions “at least partially”, “at least a partial” or “at least a part of”, as used herein, may mean at least 5 % thereof, in particular at least 10 % thereof, in particular at least 15 % thereof, in particular at least 20 % thereof, in particular at least 25 % thereof, in particular at least 30 % thereof, in particular at least 35 % thereof, in particular at least 40 % thereof, in particular at least 45 % thereof, in particular at least 50 % thereof, in particular at least 55 % thereof, in particular at least 60 % thereof, in particular at least 65 % thereof, in particular at least 70 % thereof, in particular at least 75 % thereof, in particular at least 80 % thereof, in particular at least 85 % thereof, in particular at least 90 % thereof, in particular at least 95
- the present invention relates to an implant based on a magnesium alloy and comprising a first portion being substantially solid and a second portion being substantially porous.
- implant may in particular mean a (medical) device that may be implanted in a human or animal body.
- the implant may have various two- or three-dimensional shapes, such as a pin, a rod, a screw, a wire, a plate, a disc, a dome or a hemisphere.
- the implant may in particular be at least partially resorbable (biodegradable) by a human or animal body once implanted.
- implant based on a magnesium alloy may in particular mean that the implant comprises a magnesium alloy (such as one magnesium alloy), in particular as an essential constitutional component thereof. It may even mean that the implant (substantially) consists of a magnesium alloy or is made of a magnesium alloy, in particular of one magnesium alloy.
- solid may in particular mean that the material concerned has a substantially homogenous and/or dense structure or texture, in particularly with only few or substantially no voids or pores.
- solid may thus also be designated as "non-porous”.
- a solid material may be characterized by a relatively low specific surface area (small ratio of surface area to mass).
- porous may in particular mean that the material concerned exhibits a plurality of voids or pores within its structure or texture, typically substantially uniformly distributed within its structure or texture.
- a porous material within the meaning of the present specification may also comprise a lattice and/or a scaffold.
- a porous material may be characterized by a relatively high specific surface area (large ratio of surface area to mass).
- the second portion of the implant may in particular have a porosity of at least 5 %, in particular of at least 7.5 %, in particular of at least 10 %, in particular of at least 12.5 %, in particular of at least 15 %, in particular of at least 20 %, in particular of at least 25 %.
- the upper limit of the porosity of the second portion of the implant is not particularly limited and the second portion of the implant may have for instance a porosity of not more than 90 %, in particular not more than 85 %, in particular not more than 80 %, in particular not more than 75 %, in particular not more than 70 %.
- porosity may in particular denote the ratio of the volume of voids to the total volume.
- the porosity can be determined by conventional porosimetric methods known to a person skilled in the art, for instance by microscopy, such as atomic force microscopy (AFM), confocal microscopy or scanning electron microscopy (SEM).
- AFM atomic force microscopy
- SEM scanning electron microscopy
- the first portion of the implant may in particular have a porosity of less than 5 %, in particular less than 3 %, in particular less than 2 %, in particular less than 1 %, in particular less than 0.5 %, and in particular approximately 0 %.
- the first portion may constitute 20 to 80 wt.-% of the implant, in particular 25 to 75 wt.-% of the implant, such as 30 to 70 wt.-% of the implant.
- the second portion may constitute 20 to 80 wt.-% of the implant, in particular 25 to 75 wt.-% of the implant, such as 30 to 70 wt.- % of the implant.
- the implant comprises one first portion being substantially solid and one second portion being substantially porous.
- the (entire) first portion may in particular be integral (i.e. not divided in parts) and the (entire) second portion may in particular be integral (i.e. not divided in parts) as well.
- the first portion may be particularly efficiently configured for fixing the implant in a body material of a human or animal being and that the second portion may be particularly efficiently configured for regenerating cartilage tissue and/or for allowing an immigration of cartilage cells and/or for accommodating stem cells, as will be explained in further detail below.
- the first portion is configured for fixing (attaching, adhering) the implant in a body material of a human or animal being, in particular in or at a bone.
- the first portion may exhibit particular mechanical properties, such as mechanical strength, which enable an appropriate and secure fixation or attachment of the implant in a body material (such as a bone) of a human or animal being.
- the first portion does not substantially disintegrate or corrode so that the secure fixation of the implant in the body material can be maintained over a long period of time, in particular over the entire life time of the implant.
- the second portion is configured for releasing magnesium ions, in particular in a controlled manner, into the surrounding tissue or body material, such as an interstitial fluid of a joint.
- the second portion possesses a relatively high specific surface area allowing for a substantial interaction between the magnesium alloy material of the second portion of the implant and for instance the interstitial fluid.
- the magnesium alloy material of the second portion of the implant may gradually disintegrate or corrode, thereby releasing magnesium ions into the interstitial fluid or the like.
- the second portion is configured for regenerating cartilage tissue and/or for allowing an immigration of cartilage cells and/or for accommodating stem cells, in particular (human or animal) mesenchymal stem cells, more specifically synovial mesenchymal stem cells.
- stem cells in particular (human or animal) mesenchymal stem cells, more specifically synovial mesenchymal stem cells.
- stem cells in particular synovial mesenchymal stem cells, may be
- the second portion could also be pre-incubated with stem cells, in particular with mesenchymal stem cells, for instance with
- mesenchymal stem cells that were isolated from a patient in vitro, before performing the implantation in a two-step procedure.
- a one-step procedure may be employed, whereby mesenchymal stem cells are taken directly from fat deposits of a patient and inserted into the implant portion, which is then implanted directly.
- the second portion comprises a lattice and/or a scaffold.
- a degradation rate corrosion rate
- a magnesium release rate (degradation rate) of the second portion is higher than a magnesium release rate of the first portion, in particular by a factor of at least two, in particular by a factor of at least five, in particular by a factor of at least ten.
- a magnesium release rate (degradation rate) of the second portion is higher than a magnesium release rate of the first portion, in particular by a factor of at least two, in particular by a factor of at least five, in particular by a factor of at least ten.
- the first portion and/or the second portion is at least partially covered by a biocompatible (thin) film.
- a biocompatible (thin) film does preferably not form part of the first portion and/or the second portion covered by the biocompatible (thin) film.
- the first portion and the second portion themselves are preferably not in the shape of a film or layer. Rather, the first portion and the second portion preferably have a three-dimensional body.
- the first portion may be at least partially covered by a (first) biocompatible film, which may be in particular configured for controlling (in particular reducing) the corrosion or degradation of the magnesium alloy material of the first portion, i.e. controlling (in particular reducing) a
- the first biocompatible film may thus also be referred to as a protective coating.
- the second portion may be at least partially covered by a (second)
- biocompatible film which may be different from the first biocompatible film.
- the second biocompatible film may also be configured for controlling (in particular reducing, but typically to a less extent than the first biocompatible film) the corrosion or degradation of the magnesium alloy material of the second portion, i.e. controlling (in particular reducing) a magnesium release rate of the second portion.
- the biocompatible (thin) film, in particular the second biocompatible film may be configured for controlling (such as increasing or decreasing) adsorption of biological molecules on a surface of the implant (in particular of the second portion), and/or for enhancing cell growth.
- the biocompatible (thin) film comprises a calcium
- phosphate in particular at least one of the group consisting of tricalcium phosphate (Ca3(P0 4 )2), octacalcium phosphate (03 8 H 2 (R0 4 ) 6 ⁇ 5H 2 0), and hydroxyapatite (Caio(P0 4 ) 6 (OH)2). These materials may ensure that
- the biocompatible film may comprise hydroxyapatite (Caio(P0 4 ) 6 (OH) 2 ), which may enhance osseointegration and/or promote bone growth, thereby rendering it
- the biocompatible (thin) film comprises one or more pharmaceutical agents, in particular one or more pharmaceutical agents that promote cell death of non-dividing stem cells.
- suitable examples thereof include dasatinib, quercetin, and navitoclax.
- the biocompatible (thin) film comprises at least one of a polymer or a glass (i.e. an amorphous silica-based material, such as bioglass).
- a polymer- or glass-based biocompatible (thin) film may be
- first portion and the second portion are made of the same material (disregarding an optional first and/or second biocompatible film).
- the first portion and the second portion may comprise the same magnesium alloy.
- the magnesium alloy comprises zinc in an amount of not more than 1.0 wt.%, and calcium in an amount of not more than 1.0 wt.%, with the balance being magnesium and inevitable impurities.
- the magnesium alloy may comprise 0.1 to 0.6 wt.% zinc, and 0.2 to 0.6 wt.% calcium, with the balance being magnesium and inevitable impurities, wherein each impurity is contained in an amount of not more than 0.01 wt.% and the sum of impurities is 0.1 wt.% or less, and wherein a quotient of the percentages by weight of zinc and calcium being less than or equal to 1, as described for instance in EP 2 857 536 Al, the entire disclosure of which is hereby incorporated herein by reference.
- the implant is shaped as a screw and/or a nail.
- the implant may be shaped as a screw, wherein the first portion is shaped as a screw thread and the second portion is shaped as a screw head.
- the first portion and the second portion are manufactured separately.
- the implant may be configured as a modular system from a first portion and a second portion provided separately.
- the implant may be provided with a particular high freedom of design from individual components of a first and a second portion, so as to individually adapt the implant to actual needs of a patient in a specific situation.
- the first portion and the second portion are preferably configured for being assembled, in particular via an interlocking screw system, during implantation.
- several smaller parts may be implanted which might reduce the stress for the patient upon surgery and may even allow for a minimally invasive or endoscopic surgery.
- the first portion and/or the second portion is obtained by a three-dimensional printing procedure.
- the desired structure or shape of the implant for example with a second portion comprising a scaffold or lattice, may be easily and reliably achieved.
- the present invention relates to a method of preparing an implant based on a magnesium alloy (such as an implant as described in the foregoing).
- the method comprises the steps of forming a first portion such that the first portion is substantially solid and forming a second portion such that the second portion is substantially porous.
- the forming of the first portion and/or the forming of the second portion comprises three-dimensional printing.
- the desired structure or shape of the implant for example with a second portion
- the method further comprises the step of forming a biocompatible (thin) film at least partially covering the first portion and/or the second portion.
- the step of forming a biocompatible (thin) film comprises (or involves) atomic layer deposition (ALD).
- Atomic layer deposition which may be referred to as a sequential chemical vapor deposition (CVP)
- CVP sequential chemical vapor deposition
- uniformity in terms of morphology and crystallinity of the thin film may be suitably achieved, in contrast to other deposition techniques, such as pulsed laser deposition, plasma spraying or sol gel techniques, which often provide poor coating/substrate adhesion and/or no uniformity in terms of morphology and crystallinity, even often resulting in amorphous layers, which have a high dissolution rate in solution.
- ALD is based on successive, surface controlled reactions of precursors from gas phase to produce thin films and overlayers with perfect conformity to surface topography and process controllability.
- Surface reactions gas/solid
- All the reactions are cyclically repeated.
- ALD allows processing uniform and homogeneous thin films, in general dense and non-porous, over small or large areas, by building one mono-atomic layer after another (or a distinct fraction thereof).
- Atomic level control ensures that extremely thin films and complex nanostructures can be processed.
- ALD can also be used to modify the interfaces or to dope a thin film at a level required, including delta-doping.
- water (H 2 0), ozone (0 3 ) or oxygen (O2) may be chosen as oxygen source for the formation of oxide layer, depending on the
- the thus obtained implant may be suitably used in the treatment, amelioration and/or prevention of osteoarthrosis or related joint diseases.
- Additional suitable application fields include dental (such as tooth implant screws), orthopedics (such as hip and knee implants, fractures) and spinal (such as spinal cage screws).
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1813525.1A GB2576706A (en) | 2018-08-20 | 2018-08-20 | Magnesium alloy based implant and method of preparing an implant |
PCT/EP2019/072291 WO2020038956A1 (en) | 2018-08-20 | 2019-08-20 | Magnesium alloy based implant and method of preparing an implant |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3840793A1 true EP3840793A1 (en) | 2021-06-30 |
Family
ID=63668224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19758677.9A Pending EP3840793A1 (en) | 2018-08-20 | 2019-08-20 | Magnesium alloy based implant and method of preparing an implant |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3840793A1 (en) |
GB (1) | GB2576706A (en) |
WO (1) | WO2020038956A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220354490A1 (en) | 2021-05-10 | 2022-11-10 | Cilag Gmbh International | Absorbable surgical staple comprising at least two coatings |
CN113425457B (en) * | 2021-06-24 | 2022-09-30 | 中山大学 | Novel belt loop magnesium plate with high strength and corrosion resistance |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8329202B2 (en) * | 2004-11-12 | 2012-12-11 | Depuy Products, Inc. | System and method for attaching soft tissue to an implant |
US8728387B2 (en) * | 2005-12-06 | 2014-05-20 | Howmedica Osteonics Corp. | Laser-produced porous surface |
DE102007023284A1 (en) * | 2007-06-15 | 2008-12-18 | Biotronik Vi Patent Ag | Implant with a near-surface magnesium-containing diffusion layer and associated production method |
DE102008019748A1 (en) * | 2008-04-18 | 2009-10-22 | Gottfried Wilhelm Leibniz Universität Hannover | Bioresorbable material |
WO2011056422A1 (en) * | 2009-11-03 | 2011-05-12 | Howmedica Osteonics Corp | Platform for soft tissue attachment |
WO2012033637A1 (en) * | 2010-09-07 | 2012-03-15 | Boston Scientific Scimed, Inc. | Bioerodible magnesium alloy containing endoprostheses |
EP2857536B1 (en) | 2013-10-03 | 2015-12-30 | Annelie-Martina Weinberg | Implant for patients in growth, method for its preparation and use |
US10675074B2 (en) * | 2017-01-27 | 2020-06-09 | Zimmer, Inc. | Porous fixation devices and methods |
-
2018
- 2018-08-20 GB GB1813525.1A patent/GB2576706A/en not_active Withdrawn
-
2019
- 2019-08-20 WO PCT/EP2019/072291 patent/WO2020038956A1/en unknown
- 2019-08-20 EP EP19758677.9A patent/EP3840793A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
GB2576706A (en) | 2020-03-04 |
GB201813525D0 (en) | 2018-10-03 |
WO2020038956A1 (en) | 2020-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hu et al. | Bioinspired surface modification of orthopedic implants for bone tissue engineering | |
Jiménez et al. | Bibliographic review on the state of the art of strontium and zinc based regenerative therapies. Recent developments and clinical applications | |
Kim et al. | Effect of the biodegradation rate controlled by pore structures in magnesium phosphate ceramic scaffolds on bone tissue regeneration in vivo | |
Alghamdi et al. | Osteogenicity of titanium implants coated with calcium phosphate or collagen type-I in osteoporotic rats | |
Ghosh et al. | Metallic biomaterial for bone support and replacement | |
John et al. | Surface modification of titanium and its alloys for the enhancement of osseointegration in orthopaedics | |
Yang et al. | Effects of biomimetically and electrochemically deposited nano-hydroxyapatite coatings on osseointegration of porous titanium implants | |
US20130121956A1 (en) | Composition for Enhancing Bone Formation | |
KR20090108604A (en) | Metal oxide scaffolds | |
Cho et al. | Promotion of osseointegration of anodized titanium implants with a 1α, 25-dihydroxyvitamin D3 submicron particle coating. | |
AU2005209861A1 (en) | Bone graft substitute | |
Pyo et al. | Bone formation on biomimetic calcium phosphate-coated and zoledronate-immobilized titanium implants in osteoporotic rat tibiae. | |
WO2020243768A9 (en) | Material for a bioresorbable implant, bioresorbable implant and method of making a bioresorbable implant | |
Noor | Nanohydroxyapatite application to osteoporosis management | |
RU88954U1 (en) | IMPLANT FOR REPLACEMENT OF BONE DEFECTS | |
EP3840793A1 (en) | Magnesium alloy based implant and method of preparing an implant | |
Shimizu et al. | Bioactive effects of strontium loading on micro/nano surface Ti6Al4V components fabricated by selective laser melting | |
Agrawal et al. | Osteoinductive and osteoconductive biomaterials | |
US20130195955A1 (en) | Implants Containing BMP-7 | |
Kozuma et al. | Osteoconductive potential of a hydroxyapatite fiber material with magnesium: In vitro and in vivo studies | |
Wang et al. | Enhanced biocompatibility and osseointegration of calcium titanate coating on titanium screws in rabbit femur | |
Chetty et al. | Synthesis, properties, and applications of hydroxyapatite | |
Jeong et al. | Acceleration of bone formation by octacalcium phosphate composite in a rat tibia critical-sized defect | |
JP6998383B2 (en) | Bone regeneration material | |
Yoo et al. | Biochemical Responses of Anodized Titanium Implants with a Poly (lactide-co-glycolide)/Bone Morphogenetic Protein-2 Submicron Particle Coating. Part 2: An In Vivo Study. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210225 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220325 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61F 2/30 20060101ALI20231013BHEP Ipc: A61F 2/28 20060101ALI20231013BHEP Ipc: A61B 17/80 20060101ALI20231013BHEP Ipc: B33Y 80/00 20150101ALI20231013BHEP Ipc: A61L 31/16 20060101ALI20231013BHEP Ipc: A61L 31/10 20060101ALI20231013BHEP Ipc: A61L 31/08 20060101ALI20231013BHEP Ipc: A61L 31/14 20060101ALI20231013BHEP Ipc: A61L 31/02 20060101AFI20231013BHEP |
|
INTG | Intention to grant announced |
Effective date: 20231115 |